What is the current Price Target for the Elevation Oncology Inc stock?

The average Elevation Oncology Inc target price is $1.06. This is 310.06% higher than the current stock price. The highest price target is 518.96%, the lowest is 170.79%. 5 Analysts have issued a price target Elevation Oncology Inc 2026 .

How high will the Elevation Oncology Inc stock rise?

No reliable answer can be given as to how high the Elevation Oncology Inc stock will rise. The performance of stocks, including the Elevation Oncology Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Elevation Oncology Inc stock today?

The performance of Elevation Oncology Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Elevation Oncology Inc stock fall?

The decline in Elevation Oncology Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Elevation Oncology Inc Forecast, price target & analysts

$0.24

6.19% today

Nasdaq, Apr 04, 05:45 pm CET

ISIN

US28623U1016

Symbol

ELEV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Elevation Oncology Inc Target price 2025 - Analyst rating & recommendation

Elevation Oncology Inc Classifications & Recommendation:

Buy

38%

Hold

63%

Elevation Oncology Inc Price Target

Target Price	$1.06
Price	$0.26
Potential	310.06% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Elevation Oncology Inc 2026 . The average Elevation Oncology Inc target price is $1.06. This is 310.06% register free of charge higher than the current stock price. The highest price target is $1.60 518.96% register free of charge , the lowest is $0.70 170.79% register free of charge .
	A rating was issued by 8 analysts: 3 Analysts recommend Elevation Oncology Inc to buy, 5 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Elevation Oncology Inc stock has an average upside potential 2026 of 310.06% register free of charge . Most analysts recommend the Elevation Oncology Inc stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.78	-0.68
	41.79%	12.82%
P/E		negative

3 Analysts have issued a Elevation Oncology Inc forecast for earnings per share. The average Elevation Oncology Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.78	41.79%
2025	$-0.68 12.82% Unlock
2026	$-0.52 23.53% Unlock
2027	$-0.67 28.85% Unlock
2028	$-0.71 5.97% Unlock
2029	$-0.61 14.08% Unlock

Current	-0.32	90.48%
2025	-0.38 18.75% Unlock
2026	-0.50 31.58% Unlock
2027	-0.39 22.00% Unlock
2028	-0.37 5.13% Unlock
2029	-0.42 13.51% Unlock

Elevation Oncology Inc...

Current Elevation Oncology Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Stephens & Co.	Locked ➜ Locked	Locked	Mar 24 2025
Citizens Capital Markets	Locked ➜ Locked	Locked	Mar 21 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 21 2025
Leerink Partners	Locked ➜ Locked	Locked	Mar 21 2025
Piper Sandler	Locked ➜ Locked	Locked	Mar 21 2025
Citizens Capital Markets	Locked ➜ Locked	Locked	Mar 10 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 10 2025

Analyst Rating	Date
Locked Stephens & Co.: Locked ➜ Locked	Mar 24 2025
Locked Citizens Capital Markets: Locked ➜ Locked	Mar 21 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 21 2025
Locked Leerink Partners: Locked ➜ Locked	Mar 21 2025
Locked Piper Sandler: Locked ➜ Locked	Mar 21 2025
Locked Citizens Capital Markets: Locked ➜ Locked	Mar 10 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 10 2025

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now